Partnership/Divestment Opportunities

Ambrilia is currently looking to partner and/or divest the following assets:

C2L (octreotide)

Indication: Acromegaly and carcinoid tumors
Status: Phase III completed and filing imminent
Rights available: US and other major markets incl. Italy, Eastern Europe, Asia (excluding Korea), Japan & South America (excluding Brazil)

Goserelin

Indication: Hormone sensitive prostate cancer
Status: Phase I/II initiated
Rights available: Worldwide

PCK3145 Therapeutic Peptide

Indication: Hormone resistant prostate cancer
Status: Phase I/II completed
Rights available: Worldwide

NGR-Delivery Technology

Indication: Cancer general
Status: Preclinical
Rights available: Worldwide

Other – PSP94 Immunoassay

Indication: Prostate cancer
Status: Clinical proof of concept with research use only kits
Rights available: Worldwide

 

Please address any interest or request for more information to:

Daniel Böck, Ph.D.
Vice-President, Business Development and Licensing
Tel.: (514) 751-2003 ext. 236
E-mail: dbock@ambrilia.com

 

Documentation

Financial Reports